Dropless Cataract Surgery Significantly Reduces Drug Costs, Study Finds

Salt Lake City, May 21, 2025 — A new study presented at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting has found that a “dropless” approach to cataract surgery can dramatically cut medication costs and simplify recovery for patients, while maintaining similar clinical outcomes to traditional eye drop regimens.

Study Highlights Dropless Protocol Benefits

The research, led by Yousef Yousef, a medical student at the University at Buffalo Jacobs School of Medicine and Biomedical Sciences, compared two postoperative care methods for cataract surgery. Traditionally, patients are prescribed a complex regimen of antibacterial and anti-inflammatory eye drops—up to 12 drops per day for four weeks. The dropless protocol, in contrast, delivers the necessary medications via injections immediately after surgery, eliminating the need for weeks of self-administered drops.

“Our study aims to underscore the benefits of the dropless cataract surgery approach as a promising alternative to the traditional drop regimen, particularly for populations where adherence to postoperative drops is challenging,” Yousef told Medscape Medical News. He hopes the findings will encourage more surgeons to adopt the dropless protocol, potentially setting a new standard of care.

Comparable Outcomes, Lower Costs

The retrospective review analyzed 544 eyes treated at a single institution: 265 eyes received the traditional drop regimen, while 279 eyes underwent the dropless protocol. The study found no significant differences in best-corrected visual acuity between the two groups. While the dropless group had a slightly higher incidence of cystoid macular edema (5% vs 1%), the rates of ocular hypertension were similar and not statistically significant.

A major advantage of the dropless approach is cost. According to a 2020 Medicare analysis, the average cost of postoperative eye drops is $228 per eye, with most expenses attributed to brand-name drugs. In contrast, the dropless protocol costs just $15.91 per eye when a single vial is used for about 10 cases.

Expert Perspectives

Dr. Neal Shorstein, a retired cataract surgeon and adviser to the Seva Foundation, noted that while randomized clinical trials are still rare, this study adds valuable observational data to the growing body of evidence supporting dropless protocols. He also highlighted the importance of medication dosage and formulation, emphasizing that the safety and effectiveness of injected drugs depend on factors such as particle size and injection site.

Looking Ahead

The dropless protocol offers three key advantages: greater convenience for patients, improved drug delivery, and significantly reduced costs. As more data emerges, this approach may become increasingly popular, especially for patients who struggle to adhere to complex drop regimens.

Disclaimer:
This article is based on findings presented at a scientific meeting and reported by Medscape Medical News. The results are from a retrospective observational study and should not be interpreted as definitive clinical guidance. Patients should consult their ophthalmologist to determine the most appropriate postoperative care for their individual needs.